Treating saphenous vein graft lesions: Drug-eluting stents are not the answer!

Area of Science:

• Cardiovascular Interventions
• Interventional Cardiology
• Vascular Surgery

Background:

• Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) is associated with significant acute and long-term complications.
• Major trials comparing drug-eluting stents (DES) and bare metal stents (BMS) in SVG lesions show no significant difference in outcomes.
• Current evidence suggests BMS may be preferred for SVG stenting due to cost-effectiveness.

Discussion:

• The lack of difference between DES and BMS in SVG PCI challenges previous assumptions about stent technology in this specific vascular bed.
• High rates of restenosis and re-occlusion persist despite advances in stent technology.
• The cost-benefit analysis favors BMS in the absence of a clear clinical advantage for DES in SVG interventions.

Key Insights:

• Long-term follow-up from large trials indicates no superiority of DES over BMS for saphenous vein graft lesions.
• Bare metal stents are a cost-effective option for SVG stenting.
• Saphenous vein graft stenting continues to be associated with high failure rates.

Outlook:

• Alternative treatment strategies, including intervention on native coronary artery lesions, are being explored.
• Future research may focus on optimizing SVG lesion management beyond traditional stenting.
• Novel approaches are needed to address the inherent challenges of SVG interventions.